Option chain shows key data for Context Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Context Therapeutics.

Context Therapeutics (NASDAQ:CNTX) Stock, Option Chain

Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

News

Initiation

Pre-Market Outlook

Analyst Ratings

Trading Ideas

CNTX

LEVI

NKTR

SMMT

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

AADI

ALRN

ATAK

ATNI

BATL

BRLI

BRSH

CHSN

CING

ELAB

EOSE

FRGT

GETR

GNLX

HSCS

ICCT

INDV

INHD

LRHC

MGRX

Nuveen Insured California Premium Fund Ii

NCPL

NCSM

NYMT

SCHL

SLGC

VRCA

VRPX

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results.

Quanex Building Products shares fell 10.7% to $30.95 on Friday.

Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

ALEC

BCYC

KIND

MNSO

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday.

Here are some other big stocks recording gains in today’s session.

Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday

Context Therapeutics Inc

Management

Press Releases

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Health Care

General

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Earnings

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Opinion

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALLO

BCAB

ERAS

ONCY

RXRX

TSX:ONC

ALT5 Sigma

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Assertio Holdings

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Grace Therapeutics

Ikena Oncology

Iterum Therapeutics

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

NRX Pharmaceuticals

Nutriband

OptiNose

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Cassava Sciences

Scilex Holding

SCYNEXIS

Veru

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Ventyx Biosciences

VYNE Therapeutics

D. Boral Capital

JMP Securities

HC Wainwright & Co.

Piper Sandler

Maxim Group

Comments

Context Therapeutics

Context Therapeutics (CNTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga